Drug Development

As Neurogene prepares for a key investor conference, all eyes are on its lead candidate for Rett syndrome. The company bets its proprietary EXACT™ technology can solve a critical gene therapy challenge, holding immense promise for patients and investors alike.

Alterome Therapeutics brings on a heavy-hitting CFO in Johanna Mylet, who guided Poseida to an IPO and Roche acquisition. What does this signal for its future?

While we focus on breakthrough drugs, the real story is often in the logistics. GCCL’s expansion into Asia-Pacific highlights the critical, and lucrative, world of clinical trial support.

With over a billion in the bank, Spyre Therapeutics is hitting the investor circuit. But cash is only half the story. Can upcoming data validate its ambitious strategy?

A small biotech is making a bold leap, leveraging its heart disease expertise to tackle Alzheimer's and Parkinson's with a novel class of brain drugs.

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

A new deal between Owkin and Boehringer Ingelheim isn't just a partnership; it's a look at the future where AI scientists and deep data drive innovation.

A new US patent allowance for Purple Biotech's modular CAPTN-3 platform bolsters its strategic position, promising safer, more precise antibody cancer treatments.

Resalis Therapeutics poaches a top clinical leader from Novo Nordisk to steer its novel RNA-based obesity drug, RES-010, through clinical trials.

As iBio heads to a key investor conference, its AI-driven antibody platform aims to solve the GLP-1 paradox: achieving sustainable weight loss by preserving muscle.

A biotech startup is targeting a hidden cause of chemo resistance. An AI firm claims it can predict a drug's success. Their deal is a major market signal.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.